<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">97621</article-id><article-id pub-id-type="doi">10.7554/eLife.97621</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.97621.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Engineered migrasomes provide a robust and thermally stable vaccination platform</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Dongju</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0007-1409-8482</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Haifang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Wan</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Zihui</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Sho</surname><given-names>Takami</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xing</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Dou</surname><given-names>Longyu</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Qiang</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yu</surname><given-names>Li</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3757-0758</contrib-id><email>liyulab@mail.tsinghua.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Zhihua</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0269-0901</contrib-id><email>zhihualiu@mail.tsinghua.edu.cn</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>The State Key Laboratory of Membrane Biology, Tsinghua-Peking Joint Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>The State Key Laboratory of Membrane Biology, Tsinghua-Peking Joint Center for Life Sciences, Institute of Immunology, School of Basic Medical Sciences, Tsinghua University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wwqze12</institution-id><institution>Clinical Stem Cell Research Center, Peking University Third Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>School of Basic Medical Sciences, Tsinghua University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>Ministry of Education Key Laboratory of Protein Sciences, Tsinghua-Peking Joint Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structures, School of Life Science, Tsinghua University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution>Migrasome Therapeutics</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Krzych</surname><given-names>Urszula</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0145znz58</institution-id><institution>Walter Reed Army Institute of Research</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04fhee747</institution-id><institution>National Institute of Immunology</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>13</day><month>11</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP97621</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-03-13"><day>13</day><month>03</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-14"><day>14</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.13.584850"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-05-20"><day>20</day><month>05</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.97621.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-06-27"><day>27</day><month>06</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.97621.2"/></event></pub-history><permissions><copyright-statement>© 2024, Wang, Wang et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Wang, Wang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-97621-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-97621-figures-v1.pdf"/><abstract><p>The growing ability of pathogens and tumor cells to evade immune surveillance underscores the urgent need for new vaccine platforms that harness diverse biological mechanisms. Logistical constraints associated with cold-chain transport further limit vaccine accessibility, particularly in resource-limited settings. Migrasomes—specialized organelles produced during cell migration—are inherently stable and enriched with immune-modulating molecules. To overcome the low yield of natural migrasomes, we engineered migrasome-like vesicles (eMigrasomes) using hypotonic shock combined with cytoskeletal disruption to promote vesicle formation. eMigrasome biogenesis depends on core migrasome machinery and recapitulates the biophysical and molecular features of native migrasomes while achieving higher production efficiency. In murine models, eMigrasomes loaded with a model antigen elicited potent antibody responses and retained structural integrity and immunogenicity at room temperature. Moreover, eMigrasomes displaying the SARS-CoV-2 Spike protein induced strong humoral responses and conferred protection against viral challenge in mice. These results establish eMigrasomes as an innovative, thermally stable, and broadly applicable vaccine platform derived from migrasome biology.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>vaccine</kwd><kwd>engineered migrasome</kwd><kwd>hypotonic shock</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/027s68j25</institution-id><institution>Ministry of Science and Technology of the People's Republic of China</institution></institution-wrap></funding-source><award-id>2024YFA1307301</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Tsinghua-Toyota Joint Research Fund</institution></institution-wrap></funding-source><award-id>20233930058</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cve4549</institution-id><institution>Tsinghua University</institution></institution-wrap></funding-source><award-id>20251080019</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32030023</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82530021</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Zhihua</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042pgcv68</institution-id><institution>Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences</institution></institution-wrap></funding-source><award-id>CI2023C024YL</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>92354306</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32330025</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Integration of migrasome-inspired biology with hypotonic shock-mediated vesicle generation establishes a durable and versatile platform for vaccine development.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>To face the imminent challenges of emerging infectious diseases, and to realize the not-yet-fulfilled promise of cancer vaccines, new types of vaccination platforms based on different basic biological principles are urgently needed. The huge success of mRNA vaccines in the fight against the Covid-19 pandemic further supports the importance of developing vaccine platforms based on different underlying biological mechanisms (<xref ref-type="bibr" rid="bib24">Park et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Polack et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Baden et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Gui et al., 2023</xref>). However, the application of mRNA-based vaccines, or other forms of traditional vaccine, has been hampered by the requirement for complicated cold-chain transportation, in which the materials are constantly maintained at low temperature (<xref ref-type="bibr" rid="bib8">Crommelin et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Grau et al., 2021</xref>). For most parts of the world, especially the Global South, it is vitally important to develop vaccines that do not require cold-chain transportation.</p><p>Migrasomes are recently discovered organelles of migrating cells (<xref ref-type="bibr" rid="bib22">Ma et al., 2015</xref>). During migrasome formation, long membrane tethers named retraction fibers are pulled out at the trailing edge of migrating cells by the force generated by the movement of the cells. Migrasomes are formed on retraction fibers by a complicated process involving multiple components (<xref ref-type="bibr" rid="bib29">Wu et al., 2017</xref>; <xref ref-type="bibr" rid="bib15">Huang et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Ding et al., 2023</xref>). In the final expansion step, the growth of migrasomes is driven by assembly of nanometer-scaled tetraspanin-enriched microdomains (TEMs) into micrometer-scaled tetraspanin-enriched macrodomains (TEMAs) (<xref ref-type="bibr" rid="bib15">Huang et al., 2019</xref>; <xref ref-type="bibr" rid="bib9">Dharan et al., 2023</xref>). Thus, migrasomes are highly enriched with components of TEMs—such as tetraspanins, integrins, and cholesterol—and formation of migrasomes is dependent on the presence of these molecules. For example, overexpression of Tspan4 can promote migrasome formation (<xref ref-type="bibr" rid="bib15">Huang et al., 2019</xref>), while removing cholesterol can block migrasome formation. Theoretical modeling, in vitro reconstitution of migrasome formation, and membrane stiffness measurement by atomic force microscopy have revealed mechanistic insights into migrasome formation. These approaches showed that tetraspanin- and cholesterol-enriched macrodomains have highly elevated membrane stiffness, which is the key factor to drive the bulging of retraction fibers into migrasomes; as a result, migrasomes are highly rigid (<xref ref-type="bibr" rid="bib15">Huang et al., 2019</xref>). More recently, it was shown that assembly of TEMs can repair damaged membranes by restricting the spread of membrane rupture. In liposomes containing Tspan4 and cholesterol, detergent-induced membrane damage can be rapidly repaired, and Tspan4-embedded liposomes are highly resistant to damage (<xref ref-type="bibr" rid="bib16">Huang et al., 2022</xref>).</p><p>One defining feature of TEMs is the enrichment of immune-modulating molecules such as members of the immunoglobulin superfamily (IgSF) (<xref ref-type="bibr" rid="bib20">Levy and Shoham, 2005</xref>; <xref ref-type="bibr" rid="bib4">Charrin et al., 2003</xref>; <xref ref-type="bibr" rid="bib6">Clark et al., 2001</xref>). This group of molecules contains many key signaling molecular complexes that regulate the immune response, including antigen receptors, antigen-presenting molecules, co-receptors, antigen receptor accessory molecules, and co-stimulatory or inhibitory molecules (<xref ref-type="bibr" rid="bib19">Lefranc and Lefranc, 2001</xref>). Since migrasomes are largely composed of TEMs, members of the IgSF are also enriched in migrasomes. This property, in addition to the high stability of migrasomes, prompted us to explore the possibility of developing a migrasome-based vaccine.</p><p>One key obstacle to developing a migrasome-based delivery system and migrasome-based vaccines is the very low yield of migrasomes. To generate migrasomes, cells must be grown at very low density to allow them to migrate, and a migrating cell can only generate a relatively low number of migrasomes in a process that takes hours to finish (<xref ref-type="bibr" rid="bib22">Ma et al., 2015</xref>). In this study, by using the biophysical insights we gained from investigating migrasome formation, we successfully overcame this key obstacle. We developed a method that mimics the key biophysical features of migrasome formation while vastly improving the yield of migrasome-like vesicles. We named these vesicles as engineered migrasomes (eMigrasomes). Using eMigrasomes loaded with the model antigen ovalbumin (OVA), we successfully demonstrate that eMigrasomes are a highly effective, room temperature (RT)-stable vaccine platform which generate a strong immunoglobulin G (IgG) response. Finally, we demonstrate that eMigrasomes loaded with SARS-CoV-2 Spike protein (S protein) can generate a strong protective humoral response against SARS-CoV-2. In summary, our study demonstrates that the eMigrasome-based vaccine platform is stable at RT, highly effective, and uses an unconventional immunological mechanism, which could be useful in certain scenarios where conventional vaccine platforms are less successful.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>By serendipity, we found that hypotonic shock induces rapid formation of migrasome-like structures on retraction fibers in Tspan4-GFP-expressing cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Similar phenomena had also been observed in recent studies (<xref ref-type="bibr" rid="bib33">Zucker et al., 2025</xref>; <xref ref-type="bibr" rid="bib30">Yoshikawa et al., 2024</xref>). 10 seconds after hypotonic shock, the Tspan4 signal started to become enriched on retraction fibers. These Tspan4-enriched domains then grew into migrasome-like structures. After reaching its peak intensity, the Tspan4-GFP signal started to diffuse away from the migrasome-like structure, which was accompanied by shrinkage of the migrasome-like structure. 440 seconds after hypotonic shock, most of the hypotonic shock-induced migrasome-like structures disappeared (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="video" rid="fig1video1">Figure 1—video 1</xref>). We found that the size of the migrasome-like structures negatively correlated with osmolarity: the lower the osmolarity, the larger the migrasome-like structures (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). To study the role of osmolarity in the formation of migrasome-like structures, we set up an imaging protocol which allowed us to carry out live-cell imaging while lowering the osmolarity in a step-wise manner (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). We found that step-wise application of the hypotonic shock significantly increased the duration time of the migrasome-like structures. In cells undergoing five steps of hypotonic shock, 50% of the migrasome-like structures were still stable 6 minutes after the final step of hypotonic shock; in contrast, in cells undergoing one step of hypotonic shock, 50% of the migrasome-like structures shrunk back or fused with their neighbors within 1.5 minutes (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>, <xref ref-type="video" rid="fig1video2">Figure 1—videos 2</xref> and <xref ref-type="video" rid="fig1video3">3</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Hypotonic stimulation-induced migrasome-like structures.</title><p>(<bold>A–M</bold>) The biogenesis of migrasome-like structures in NRK cells stably expressing Tspan4-GFP. In these images, the fluorescence intensity of Tspan4-GFP is shown in a color map scale from purple (low) to yellow (high). (<bold>A</bold>) Image series of the biogenesis of migrasome-like structures. Cells were treated with hypotonic Dulbecco’s phosphate-buffered saline (DPBS) with an osmolarity of 76.3 mOsmol and imaged using a confocal microscope. Scale bar, 10 μm. (<bold>B</bold>) Representative confocal images of cells treated with DPBS with various osmolarities. 305 mOsmol represents an isotonic condition in which no migrasome-like structures were observed. DPBS diluted to 152.5, 76.3, or 50.8 mOsmol was used to achieve hypotonic stimulations of different magnitude. The size of migrasome-like structures increased as the osmolarity was reduced. Scale bars, 10 μm (upper panels) and 5 μm (lower panels). (<bold>C</bold>) For each migrasome-like structure in (<bold>B</bold>), the whole lifetime, including the growth and shrinkage, was recorded by time-lapse imaging. The largest diameter reached during the lifetime was measured. The average diameter of migrasome-like structures increased significantly as the osmolarity was reduced. For hypotonic stimulation at 152.5, 76.3, or 50.8 mOsmol, n=194, 261, 165 migrasome-like structures, respectively. Data were plotted as mean ± SD. (<bold>D</bold>) Illustration of the experimental setup for real-time imaging of the induction of migrasome-like structures. (<bold>E</bold>) Image series of cells treated with hypotonic DPBS in two different approaches. The osmolarity of DPBS was reduced to 76.3 mOsmol by either one single step (upper panel) or five steps with 1-minute intervals (lower panel). For the step-wise reduction, the osmolarity was lowered by 25% in each step. Imaging time points were counted from the final stimulation step. Migrasome-like structures induced by the stepwise protocol showed significantly enhanced stability. Scale bars, 5 μm. (<bold>F</bold>) Statistical analysis of growth curves of migrasome-like structures in (<bold>E</bold>). Data were plotted as mean + SD. For single step stimulation, n=16 cells; for step-wise stimulation, n=13 cells. (<bold>G</bold>) Representative confocal images showing the effect of latrunculin A (LatA) treatment on the biogenesis of migrasome-like structures. Cells were pre-incubated with 0, 0.25, 0.5, or 1 μM LatA for 10 minutess and then treated with a five-step hypotonic stimulation as described in (<bold>E</bold>). LatA enhanced the biogenesis of migrasome-like structures in a dose-dependent manner. The white line indicates the boundary of the cell body. Scale bars, 10 μm. (<bold>H</bold>) Statistical analysis of the number of migrasome-like structures per cell in (<bold>G</bold>). Data were plotted as mean ± SD, for LatA treatment at 0, 0.25, 0.5, or 1 μM, n=10, 12, 14, or 9 cells were analyzed, respectively. (<bold>I</bold>) Relative mRNA level of SWELL1 analyzed by qPCR. SWELL1 expression was significantly reduced in SWELL1-knockdown (KD) cells compared to control cells. Data were plotted as mean + SD, n=3. (<bold>J</bold>) Representative confocal images of control or SWELL1-KD cells. Cells were treated with a five-step hypotonic stimulation at 2-minute intervals. The osmolarity was reduced by 1/6 in each step. Migrasome-like structures are shown in the inserts. Scale bars, 10 μm. Inset scale bars, 5 μm. (<bold>K</bold>) Statistical analysis of the diameter of migrasome-like structures in (<bold>J</bold>); data were plotted as mean ± SD, n=63 for control cells and 167 for SWELL1-KD cells. (<bold>L</bold>) Representative confocal images showing the effect of extracellular cations on the biogenesis of migrasome-like structures. Before stimulation, the culture medium was replaced by modified DPBS in which either Na<sup>+</sup>, K<sup>+</sup>, or Cs<sup>+</sup> was the only cation source. Cells were then treated with a five-step hypotonic stimulation at 2-minute intervals. The osmolarity was reduced by 1/6 in each step. Scale bars, 10 μm (upper panels) and 5 μm (lower panels). (<bold>M</bold>) Statistical analysis of the diameter of migrasome-like structures in (<bold>l</bold>); data were plotted as mean ± SD, n=18 for Na<sup>+</sup>, 119 for K<sup>+</sup>, and 203 for Cs<sup>+</sup>. (<bold>N</bold>) Multiple primary cell types and cell lines are capable of producing eMigrasomes. Cells were stained with WGA-AF488 (Thermo, W11261) after hypotonic induction of eMigrasome with our protocol. Z-stack image series were captured and sum-slices projections were applied. Scale bars, 10 μm (upper panels) and 5 μm (lower panels). For all statistical analyses in this figure, <italic>P</italic> values were calculated using a two-tailed unpaired nonparametric test (Mann–Whitney test). <italic>P</italic> value&lt;0.05 was considered statistically significant. ***<italic>P</italic>&lt;0.001; ****<italic>P</italic>&lt;0.0001.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original statistical data for <xref ref-type="fig" rid="fig1">Figure 1C, F, H, I, K and M</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97621-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97621-fig1-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-97621-fig1-video1.mp4" id="fig1video1"><label>Figure 1—video 1.</label><caption><title>Time-lapse movie showing the biogenesis of migrasome-like structures.</title><p>Related to <xref ref-type="fig" rid="fig1">Figure 1A</xref>. Scale bar, 10 μm.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-97621-fig1-video2.mp4" id="fig1video2"><label>Figure 1—video 2.</label><caption><title>The dynamics of migrasome-like structures induced by single-step approach.</title><p>Related to the upper panel of <xref ref-type="fig" rid="fig1">Figure 1E</xref>. Scale bar, 10 μm.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-97621-fig1-video3.mp4" id="fig1video3"><label>Figure 1—video 3.</label><caption><title>The dynamic of migrasome-like structures induced by a stepwise approach.</title><p>Related to the lower panel of <xref ref-type="fig" rid="fig1">Figure 1E</xref>. Scale bar, 10 μm.</p></caption></media></fig-group><p>We realized that the amount of migrasome-like structures generated by hypotonic shock depends on the number of retraction fibers. We also realized that the majority of the plasma membrane can be the source of membrane for migrasome-like structures. We reasoned that if we shrink the cells by disrupting the cytoskeleton, the shrinkage will cause the retraction of the cell edge toward the center. At the same time, the cells will be adhering to the bottom of the culture plate at various points by focal adhesion. These adhesion sites will keep the plasma membrane in place, thus serving as anchor points for generation of membrane tethers. If this scenario is true, contraction of the cell will generate large numbers of membrane tubes in a way similar to retraction fiber formation during migration. To test this hypothesis, we treated cells with different doses of latrunculin A (LatA), a reagent widely used for disruption of microfilaments, before applying the step-wise hypotonic shock. As expected, we found that treating cells with LatA caused shrinking of the cells. We also observed the massive formation of membrane tethers in the area which was occupied by the cell before shrinkage. Importantly, we observed significantly enhanced formation of migrasome-like structures from these newly formed membrane tethers in a LatA dose-dependent manner (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>).</p><p>It is well established that cells can counter a change of osmolarity with regulated volume change (<xref ref-type="bibr" rid="bib13">Hoffmann et al., 2009</xref>). To test whether regulated volume change can affect the formation of migrasome-like structures, we knocked down SWELL1, a key component of the volume-regulated anion channel that maintains a constant cell volume in response to osmotic changes (<xref ref-type="bibr" rid="bib26">Qiu et al., 2014</xref>; <xref ref-type="bibr" rid="bib28">Voss et al., 2014</xref>). We found that knockdown of SWELL1 significantly enhanced the formation of migrasome-like structures. This result suggests that the formation of migrasome-like structures can be enhanced by reducing the capacity of cells to regulate their volume during osmolarity change (<xref ref-type="fig" rid="fig1">Figure 1I–K</xref>).</p><p>Under normal physiological conditions, the extracellular space typically contains a substantial amount of sodium. Throughout all the aforementioned experiments, the buffer employed predominantly consisted of sodium as the prevailing cation. Cations are known for their role in regulation of cell volume. Next, we tested the effect of different cations on the formation of migrasome-like structures. We reasoned that if different cations have different abilities to regulate cell volume during osmolarity change, we may be able to find an easy way to attenuate the regulated cell volume change, thus promoting the formation of migrasome-like structures. To do that, we first replaced the medium with isotonic buffers containing different cations, then we added water step-wise to reduce the osmolarity. We found that indeed different cations have different abilities to promote the generation of migrasome-like structures. Substitution of sodium with equal molar potassium or cesium significantly enhanced the generation of migrasome-like structures (<xref ref-type="fig" rid="fig1">Figure 1L and M</xref>).</p><p>Tspan4 is the key protein that promotes migrasome formation, and all the experiments described above were carried out in Tspan4-GFP-expressing cells. To test whether Tspan4 can promote the formation of migrasome-like structures, we treated mCherry- or Tspan4-mCherry-expressing cells with step-wise hypotonic shock and then observed the formation of migrasome-like structures by WGA staining, which labels migrasomes effectively (<xref ref-type="bibr" rid="bib5">Chen et al., 2019</xref>). We found that indeed Tspan4-mCherry significantly enhanced the formation of migrasome-like structure (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Similar results held for Tspan1 and CD82, which are also migrasome-promoting tetraspanins (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Previously, we reported that cholesterol is essential for migrasome formation. We treated cells with methyl-beta-cyclodextrin (MβCD), which selectively extracts cholesterol from the plasma membrane. We found that the addition of MβCD rapidly destroyed the readily formed migrasome-like structures (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). This suggests that, similar to migrasomes, the structural integrity of migrasome-like structures depends on cholesterol. Recently, we reported that the formation of migrasomes is dependent on SMS2. We found that treating cells with SMS2-IN-1, a selective inhibitor of SMS2, significantly inhibits the formation of migrasome-like structures (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>). Finally, we tested whether the formation of migrasome-like structures can occur in cells other than NRK cells. Indeed, all the cells we tested were able to support the formation of migrasome-like structures (<xref ref-type="fig" rid="fig1">Figure 1N</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mechanistic and morphologic similarity between migrasomes and eMigrasomes.</title><p>(<bold>A</bold>) Representative confocal images showing the effect of Tspan4-GFP in the biogenesis of migrasome-like structures. NRK cells were transiently transfected with mCherry vector or Tspan4-mCherry. The two populations of transfected cells were mixed in a 1:1.5 ratio in a test tube and then seeded in a confocal chamber. Cells were pre-incubated with 2 μM LatA for 10 minutess and then treated with a three-step hypotonic stimulation with 2-minute intervals. In each step, the osmolarity was reduced by 1/6 (16.7%). WGA-AF647 (Thermo, W32466) was then added to stain migrasome-like structures. Z-stack images were captured for further analysis. Scale bars, 10 μm. Inset scale bars, 5 μm. (<bold>B</bold>) Statistical analysis of the number of migrasome-like structures per cell in NRK cells transiently transfected with mCherry vector or Tspan4-mCherry in (<bold>A</bold>). Data were plotted as mean ± SD, n=53, 53 cells, respectively. (<bold>C</bold>) Statistical analysis of the number of migrasome-like structures per cell in NRK cells transiently transfected with mCherry vector (n=26 cells) or CD82-mCherry (n=44 cells) in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>. Data were plotted as mean ± SD. (<bold>D</bold>) Statistical analysis of the number of migrasome-like structures per cell in NRK cells transiently transfected with mCherry vector (n=31 cells) or Tspan1-mCherry (n=44 cells) in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>. Data were plotted as mean ± SD. (<bold>E</bold>) Representative confocal images showing the effect of cholesterol extraction on migrasome-like structures. NRK cells stably expressing Tspan4-GFP were stimulated to generate migrasome-like structures as described in (<bold>A</bold>). Cells were then incubated with 10 mM MβCD or buffer supplied with an equal volume of control solvent (H<sub>2</sub>O) for 30 minutes before imaging. Z-stack images were captured for further analysis. Scale bars, 10 μm. Inset scale bars, 5 μm. (<bold>F</bold>) Statistical analysis of the number of migrasome-like structures per cell in control cells (n=56) or cells treated with 10 mM MβCD (n=58) in (<bold>E</bold>). Data were plotted as mean ± SD. (<bold>G</bold>) Representative confocal images showing the effect of sphingomyelin depletion on the biogenesis of eMigrasomes. NRK cells stably expressing Tspan4-GFP were incubated with DMSO or 25 μM SMS2-IN-1 for 16 hours. Cells were then treated and imaged as described in (<bold>A</bold>). Scale bars, 10 μm. Inset scale bars, 5 μm. (<bold>H</bold>) Statistical analysis of the number of migrasome-like structures per cell in control cells (n=51) or cells treated with 25 μM SMS2-IN-1 (n=46) in (<bold>G</bold>). Data were plotted as mean ± SD. (<bold>I</bold>) Representative confocal images showing a cell generating natural migrasomes (left) and eMigrasomes (right). Migrasomes and eMigrasomes are morphologically similar. The fluorescence signal of Tspan4-GFP is highly enriched in both migrasomes and eMigrasomes. Scale bars, 10 μm. Inset scale bars, 5 μm. For all statistical analyses in this figure, <italic>P</italic> values were calculated using a two-tailed unpaired nonparametric test (Mann–Whitney test). <italic>P</italic> value&lt;0.05 was considered statistically significant. ***<italic>P</italic>&lt;0.001; ****<italic>P</italic>&lt;0.0001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original statistical data for <xref ref-type="fig" rid="fig2">Figure 2B, C, D, F and H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97621-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97621-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>The effect of tetraspanin expression on the formation of migrasome-like structures.</title><p>(<bold>A</bold>) NRK cells were transiently transfected with mCherry vector or CD82-mCherry. The cells were then treated and imaged as described in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. Scale bar, 10 μm. Inset scale bars, 5 μm. (<bold>B</bold>) NRK cells were transiently transfected with mCherry vector or Tspan1-mCherry. The cells were then treated and imaged as described in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. Scale bar, 10 μm. Inset scale bars, 5 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97621-fig2-figsupp1-v1.tif"/></fig></fig-group><p>Because of the mechanistic similarity between migrasomes and migrasome-like structures (<xref ref-type="fig" rid="fig2">Figure 2I</xref>), and because of the artificial nature of the procedure to generate these structures, we named these migrasome-like structures as engineered migrasomes (eMigrasomes).</p><p>Based on these results, we designed a protocol to generate and isolate eMigrasomes (eMigs) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). In this protocol, cells cultured in flasks were pretreated with high-potassium DPBS (K-DPBS) containing LatA and then the osmolarity was reduced by adding water in a step-wise manner. The flask then was subjected to moderate rotation to separate poorly adhering cell bodies and tightly adhering eMigrasomes. The supernatant containing the majority of cell bodies was discarded, and the eMigrasomes attached to the bottom were harvested by pipetting. No trypsinization was applied to ensure optimal protection of the integrity of eMigrasomes. To remove remaining cell bodies, crude eMigrasomes were subjected to differential centrifugation followed by a gravity-dependent filtration through a 6 μm filter. eMigrasomes in the flowthrough were concentrated by high-speed centrifugation. This protocol generated eMigrasomes in a high yield. By microscopic examination, every individual cell robustly generates eMigrasomes (<xref ref-type="video" rid="fig3video1">Figure 3—video 1</xref>). By confocal microscopy analysis, the isolated eMigrasomes are round vesicles with different sizes (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). To measure the size of eMigrasomes, we carried out a confocal-based analysis using Hough circle transformation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We found that eMigrasomes have a size range from 1.4 to 6.6 μm, with a median size of 1.6 μm (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Since negative staining might distort the shape of membrane vesicles (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), we carried out cryo-EM analysis of eMigrasomes. Under cryo-EM, eMigrasomes appeared as intact round vesicles (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Notably, the eMigrasomes were not contaminated with significant amounts of intracellular membranes, as western blotting of purified eMigrasomes showed very little contamination from other organelles (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Isolation and characterization of eMigrasome.</title><p>NRK cells stably expressing Tspan4-GFP were used in all experiments in this figure if not otherwise specified. (<bold>A</bold>) Schematic illustration showing the process of eMigrasome induction, isolation, and purification. (<bold>B</bold>) Confocal image (left), threshold edge (middle), and centroid map (right) of purified eMigrasomes. Image processing and analysis were performed using ImageJ. The Hough circle transform plugin was applied to recognize and transform thresholded edges into binned objects representing individual eMigrasomes. Scale bar, 10 μm. Inset scale bar, 5 μm. (<bold>C</bold>) Statistical analysis of the radius of purified eMigrasomes. Measurement was performed using the map generated by Hough circle transformation analysis. 4725 particles were analyzed and the data were binned to plot the distribution of eMigrasomes radius. (<bold>D</bold>) TEM micrograph of negatively stained purified eMigrasomes. Scale bar, 1 μm. (<bold>E</bold>) Cryo-EM micrograph of purified eMigrasomes. Scale bar, 200 nm. (<bold>F</bold>) Western blot showing the protein level of several markers in cell bodies (Cell) and eMigrasomes (eMig). An equal amount of protein was loaded in each lane. (<bold>G</bold>) Representative time-lapse confocal images showing the high permeability of eMigrasomes to Cy5 at 1.5 hours post purification (left) and the gradual increase in the permeability of eMigrasomes to 40 kDa dextran-TMR (right). Scale bars, 5 μm. (<bold>H</bold>) Statistical analysis of the percentage of eMigrasomes (eMigs) that were permeable to 40 kDa dextran-TMR at the indicated time points. For each time point, eMigrasomes from three different views were analyzed (data were plotted as mean ± SD, n=3). From left to right, 336, 493, 812, 830, and 631 eMigrasomes were analyzed. (<bold>I</bold>) Representative confocal images of eMigrasomes after sitting at room temperature for 0, 3, 7, or 14 days. Aliquots of eMigrasomes were stored in EP tubes as pellets at room temperature for the indicated time, then resuspended and dropped into a confocal chamber before imaging. Z-stack image series were captured and sum-slices projections were applied. Scale bar, 10 μm. Inset scale bar, 5 μm. (<bold>J</bold>) Number of eMigrasomes after storage at room temperature for 0, 3, 7, or 14 days. Aliquots of eMigrasomes (7 × 10<sup>6</sup> eMigrasomes per tube in black, 3 × 10<sup>6</sup> eMigrasomes per tube in green) were stored in EP tubes as pellets at room temperature for the indicated time, then resuspended and stained with WGA561 before counting by FACS. (<bold>K</bold>) Time-lapse image series showing purified eMigrasomes treated with 10 mM MβCD or control buffer. A 10 μl drop of concentrated eMigrasomes was settled in a confocal chamber, then sealed and maintained at 37°C during imaging. Buffer containing 10 mM MβCD or control solvent was added to the drop using the equipment illustrated in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. Scale bars, 10 μm (left panels) and 5 μm (right panels).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig3">Figure 3F</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97621-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig3">Figure 3F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97621-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Original statistical data for <xref ref-type="fig" rid="fig3">Figure 3C, H and J</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97621-fig3-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97621-fig3-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-97621-fig3-video1.mp4" id="fig3video1"><label>Figure 3—video 1.</label><caption><title>4D time-lapse movie showing the biogenesis of eMigrasomes.</title><p>Related to <xref ref-type="fig" rid="fig3">Figure 3</xref>. Scale, each grid represents 20 μm in x, y, or z axis.</p></caption></media></fig-group><p>Previously, we reported that migrasomes can become leaky before rupture. We wondered whether eMigrasomes can also become leaky. To test this, we added eMigrasomes into isolation buffer loaded with Cy5 and 40 kDa dextran-TMR. At RT, eMigrasomes rapidly become leaky to Cy5, a fluorescent dye that does not pass intact membranes (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). During the 48 hours after preparation, eMigrasomes gradually become leaky to 40 kDa dextran-TMR, which mimics the size of a normal protein (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>).</p><p>Next, we tested the stability of eMigrasomes at RT. Surprisingly, eMigrasomes are highly stable. Even after 14 days at RT, the morphology of eMigrasomes did not change significantly, and the number of eMigrasomes was only slightly reduced (<xref ref-type="fig" rid="fig3">Figure 3I and J</xref>). However, if we treated isolated eMigrasomes with MβCD, most of them deformed and ruptured within 30 minutes (<xref ref-type="fig" rid="fig3">Figure 3K</xref>). This suggests a crucial contribution of cholesterol to the stability of isolated eMigrasomes.</p><p>The stable nature of eMigrasomes prompted us to explore the possibility of using eMigrasomes as carriers for delivery of proteins (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). We found that membrane proteins (e.g., the cell surface receptor PD1) can be easily loaded onto eMigrasomes by simply overexpressing these proteins in cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). To load cytosolic proteins, we fused them with the transmembrane domain followed by the polybasic tail of syntaxin 2 (STX2). This allowed us to successfully load the cytosolic protein OVA onto the plasma membrane and thus onto eMigrasomes, referred to as mOVA for membrane-tethered OVA (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>eMigrasomes as an antigen carrier for vaccination.</title><p>(<bold>A</bold>) Schematic illustration of strategies for loading proteins of interest (POI) onto eMigrasomes. The protocol includes the construction of antigen-encoding plasmids, the construction of engineered cell lines stably expressing the antigens, and the production of antigen-loaded eMigrasomes. Membrane proteins, which already carry a transmembrane (TM) domain, are overexpressed in cells (top). Cytosolic proteins are membrane tethered by tagging with the TM sequence and polybasic tail of STX2 (bottom). Cells are then treated with hypotonic buffer to enrich the POI on the surface of eMigrasomes. (<bold>B</bold>) Representative confocal image of a cell expressing PD1-mCherry and Tspan4-GFP. The transmembrane protein PD1-mCherry was loaded onto eMigrasomes as shown in the top part of (<bold>A</bold>). Scale bars, 10 μm. Inset scale bars, 5 μm. (<bold>C</bold>) Representative confocal image of a cell expressing membrane-tethered OVA-mCherry (mOVA-mc) and Tspan4-GFP. To create an extracellular membrane-tethered form of OVA (mOVA), the sequence of OVA was fused to the C-terminus of a truncated form of mouse STX2, in which only the transmembrane region and a polybasic tail remained. The mCherry tag was fused to the C-terminus of OVA to trace the localization of this fusion protein. The soluble protein OVA was loaded onto the membrane of eMigrasomes, as shown in the bottom part of (<bold>A</bold>). Scale bars, 10 μm. Inset scale bars, 5 μm. (<bold>D</bold>) Representative confocal image of eMigrasomes isolated from MCA-205 cells stably expressing Tspan4-GFP and mOVA-mCherry (eM-OVA). Scale bar, 10 μm. Inset scale bar, 5 μm. (<bold>E</bold>) Western blot showing the amount of full-length mOVA-mCherry protein in host cell and eM-OVA. Cell lysate (<bold>C</bold>) containing 1 μg total protein and purified eM-OVA samples containing 0.1, 0.3, or 1 μg total protein were loaded. The protein-immobilized PVDF membrane was firstly incubated with anti-OVA antibody and then stripped and re-blotted with anti-mCherry antibody. The antigen mOVA-mCherry was highly enriched in eMigrasomes compared to host cells. MCA-205 cells stably expressing Tspan4-GFP and mOVA-mCherry were used for all experiments in the rest of this figure if not otherwise specified. (<bold>F</bold>) Amount of OVA-specific IgG in mouse serum on day 14 after intravenous (i.v), nasal, or subcutaneous (s.c) immunization with eM-OVA (20 µg/mouse). OVA-specific IgG was quantified by ELISA. Data were plotted as mean ± SD, n=4 mice were analyzed for each group. (<bold>G</bold>) ELISA quantification of OVA-specific IgG in sera from wild-type (WT) mice on day 14 after tail intravenous immunization with eM-OVA at the indicated dose. Data were plotted as mean ± SD. For 1, 3, 10, 20 µg/mouse eM-OVA immunization, n=5 mice; for 40 µg/mouse eM-OVA immunization, n=6. (<bold>H</bold>) ELISA quantification of OVA-specific IgG in sera from WT mice on day 14 after tail intravenous immunization with eM-OVA (20 µg/mouse, n=6 mice) or intraperitoneal immunization with Alum/OVA (n=5 mice). Data were plotted as mean ± SD. (<bold>I</bold>) Titer analysis of OVA-specific IgG1, IgG2b, IgG2c, and IgG3 in the sera from mice immunized with eM-OVA (20 µg/mouse, n=6 mice) or Alum/OVA (n=5 mice). Serum samples were collected on day 14. Each dot represents an individual serum sample. Data were plotted as mean ± SD. (<bold>J</bold>) Illustration of the experimental setup for assaying the stability of eM-OVA. (<bold>K</bold>) Immunoblotting analysis of the amount of OVA protein in samples of eM-OVA that were left at room temperature for 0, 3, 7, or 14 days. 2 µg protein was loaded in each lane. (<bold>L</bold>) ELISA quantification of OVA-specific IgG in sera from WT mice on day 14 after tail intravenous immunization with eM-OVA stored at room temperature for 0 days (D0, n=5 mice), 3 days (D3, n=5 mice), 7 days (D7, n=6 mice), or 14 days (D14, n=5 mice). Data were plotted as mean ± SD. 20 µg eM-OVA was injected per mouse. For all statistical analyses in this figure, <italic>P</italic> values were calculated using a two-tailed unpaired nonparametric test (Mann–Whitney test). <italic>P</italic> value&lt;0.05 was considered statistically significant. n.s. <italic>P</italic>&gt;0.05; *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4E and K</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97621-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4E and K</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97621-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Original statistical data for <xref ref-type="fig" rid="fig4">Figure 4F, G, H, I and L</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97621-fig4-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97621-fig4-v1.tif"/></fig><sec id="s2-1"><title>An eMigrasome-based vaccine</title><p>Next, we explored the potential of eMigrasomes as an antigen carrier for vaccines. First, we employed OVA, a well-established model antigen, to evaluate eMigrasomes as a platform for antigen delivery. We used imaging and immunoblotting to confirm the presence of the mOVA-mCherry protein (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>). It is worth noting that the mOVA antigen was highly enriched in isolated eMigrasomes compared to the host cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). We immunized mice with OVA-loaded eMigrasomes (eM-OVA) via different routes and found that intravenous injection resulted in the highest IgG antibody titer (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). eM-OVA induced the antigen-specific IgG response in a dose-dependent manner (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). The IgG response induced by eM-OVA at 20 μg/mouse was comparable to traditional Alum/OVA at 50 μg/mouse (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Together, these data suggest that eM-OVA elicits a strong IgG response compared to traditional alum-based immunization.</p><p>IgG is the most abundant immunoglobulin in human and mouse, with four different subtypes: IgG1, IgG2, IgG3, and IgG4 in human, and IgG1, IgG2a/c, IgG2b, IgG3 in mouse (<xref ref-type="bibr" rid="bib23">Martin et al., 1998</xref>). Different IgG subtypes are highly conserved, but each has its unique immunological functions, for example, acting through different Fc-gamma receptors (FcγRs) or binding to complement (<xref ref-type="bibr" rid="bib27">Vidarsson et al., 2014</xref>). Thus, we characterized the type of IgG induced by eM-OVA in mice and compared it to that induced by Alum/OVA. The IgG response to Alum/OVA was dominated by IgG1, consistent with previous publications (<xref ref-type="bibr" rid="bib7">Comoy et al., 1997</xref>; <xref ref-type="bibr" rid="bib14">Hogenesch, 2012</xref>). Quite differently, eM-OVA induced an even distribution of IgG subtypes, including IgG1, IgG2b, IgG2c, and IgG3 (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). Usually, the ratio between IgG1 and IgG2a/c indicates a Th1 or Th2-type humoral immune response. Thus, eM-OVA immunization induces a balance of Th1/Th2 immune responses.</p><p>Next, we assessed the stability of the immunogenicity of eM-OVA over a period of 14 days at RT. For this purpose, we placed the purified eM-OVA in a test tube at RT without adding any reagents to inhibit protein degradation. After 14 days of RT storage, the amount of intact OVA was roughly the same as in freshly purified eM-OVA, and the IgG response induced by eM-OVA remained unchanged during this period (<xref ref-type="fig" rid="fig4">Figure 4J–L</xref>).</p></sec><sec id="s2-2"><title>An eMigrasome-based vaccine induces a strong humoral protective response against SARS-CoV-2</title><p>We next explored eMigrasomes as a platform to carry the SARS-CoV-2 Spike protein (S protein). To prevent the S protein from being broken down by proteases, we mutated the furin site of the S protein. MCA-205 cells were used to express the S protein with an mCherry tag. After isolating the eMigrasomes, we used imaging to confirm the presence of the Spike protein (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). To assess the antigen integrity, we performed immunoblotting using antibodies against both S1 and mCherry. Two distinct bands were observed: one at the expected molecular weight of the S-mCherry fusion protein, and a higher molecular weight band that may represent oligomerized or higher-order forms of the Spike protein (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Furthermore, we performed confocal microscopy using a monoclonal antibody against Spike. Co-localization analysis revealed strong overlap between the mCherry fluorescence and anti-Spike staining, confirming the proper presentation and surface localization of intact S-mCherry fusion protein on eMigrasomes (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). These results confirm the structural integrity and antigenic fidelity of the Spike protein expressed on eMigrasomes.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>An eMigrasome-based vaccine induces a strong humoral protective response against SARS-CoV-2.</title><p>(<bold>A</bold>) Representative confocal images showing the presence of Spike-mCherry (S-mc) in engineered cells and isolated eMigrasomes. Scale bars, 10 μm. Inset scale bars, 5 μm. (<bold>B</bold>) Western blot showing the amount of full-length Spike-mCherry protein in eM-S. A titration (1, 2, 5, 10, 20, or 50 ng) of recombinant spike protein was loaded as standards. Purified eM-NC or eM-S samples containing 1 μg total protein were loaded. (<bold>C</bold>) Representative confocal images showing the presence of integral spike protein in isolated eMigrasomes. Scale bars, 10 μm. Inset scale bars, 5 μm. (<bold>D</bold>) Schematic diagram of the experimental procedure for immunization with Spike-loaded eMigrasomes (eM-S) and collection of serum. (<bold>E</bold>) Illustration of the rVSV-venus-SARS-CoV-2 system. VSV-Venus-SARS-CoV-2 was mixed with vaccinated mice sera. Vero-TMPRSS2 cells were infected with the reporter virus/serum mixture with an MOI of 0.01. 40 hours post-infection, the Venus-positive infected cells were quantified to estimate the NT<sub>50</sub> value for each serum. (<bold>F</bold>) Spike-specific IgG was quantified in WT mice immunized with eM-S (20 µg/mouse, i.v.) at different time points. Data were plotted as mean ± SD. Each symbol represents one individual animal, n=6 mice were analyzed. (<bold>G</bold>) Neutralization curves are presented for sera from primary-vaccination and boost-vaccination. Data were plotted as mean + SEM, n=6 mice were analyzed. Nonlinear regression was performed using the equation for the normalized response versus the inhibitor, incorporating a variable slope. (<bold>H</bold>) NT<sub>50</sub> of individual mouse in vaccinated groups was compared by <italic>P</italic>-value (paired <italic>t</italic>-test) and is indicated. Dotted lines represent assay limits of detection. Each line represents an individual mouse, n=6 mice were analyzed.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig5">Figure 5B</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97621-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97621-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Original statistical data for <xref ref-type="fig" rid="fig5">Figure 5F–H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97621-fig5-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97621-fig5-v1.tif"/></fig><p>Immunization of WT C57BL/6J mice with the Spike-loaded eMigrasomes (eM-S) resulted in a strong antibody response against the S protein, which was further improved by a second shot (<xref ref-type="fig" rid="fig5">Figure 5D and F</xref>). To assess the neutralizing capacity of the antisera provoked by eM-S, we utilized a replication-competent, infectious VSV chimera incorporated with the SARS-CoV-2 spike protein for a neutralization test (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), similar to the previously reported system (<xref ref-type="bibr" rid="bib3">Case et al., 2020b</xref>; <xref ref-type="bibr" rid="bib2">Case et al., 2020a</xref>). This genetically altered VSV chimera virus features the SARS-CoV-2 spike protein, substituting its native surface glycoprotein (G), making the VSV chimera reliant on the SARS-CoV-2 spike protein for cellular entry. The Venus-based fluorescence reporter system offers high sensitivity. The neutralizing power of antisera against the SARS-CoV-2 spike protein was assessed by calculating the percentage of Venus-positive infected cells when treated with serum versus mock controls. The antisera, stimulated by an initial immunization with eM-S, neutralized the recombinant VSV-Venus-SARS-CoV2 up to a dilution titer of approximately 300 to achieve 50% neutralization (NT<sub>50</sub>). A secondary booster immunization further enhanced the neutralization capability with an NT<sub>50</sub> up to 4000 (<xref ref-type="fig" rid="fig5">Figure 5G and H</xref>). Together, these results indicate that antigen-carrying eMigrasomes can induce a strong humoral protective response against SARS-CoV-2.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this article, we describe a method to rapidly generate eMigrasomes from cultured mammalian cells. We developed a simple method to load membrane or cytosolic proteins onto eMigrasome. Using OVA as a model antigen, we demonstrate that eMigrasomes are a highly effective, temperature-stable vaccine platform which can elicit antibody response with a very small amount of antigen. Finally, we show that eMigrasomes can be used to generate effective vaccines against SARS-CoV-2. Collectively, our study provides the proof of concept for developing eMigrasome-based vaccines.</p><p>Previously, migrasomes have been defined as ‘migration-dependent&quot; vesicles. In this study, we demonstrated that migrasome-like structures can be induced through the relative movement of the cell edge in a migration-independent manner. Notably, eMigrasomes exhibit conserved genetic and morphological features compared to natural migrasomes, providing strong evidence for this concept. Accordant with our study, a recent investigation has revealed that cell shrinkage induced by bacterial toxins can also trigger migrasome formation (<xref ref-type="bibr" rid="bib21">Li et al., 2024</xref>).</p><p>In this study, we demonstrate the efficiency of eMigrasome-based vaccines using a model antigen or an antigen from a coronavirus. The benefit of using a model antigen is that there are readily available experimental systems. The benefit of using a well-characterized virus antigen is that it allows us to reliably test the efficacy of our vaccine platform in a realistic setting. It should be noted that both a signal peptide and a transmembrane domain are necessary for proper antigen presentation on eMigrasomes. For antigens that do not naturally contain these two features, a non-native signal peptide or an artificial transmembrane domain should be engineered into the coding sequence of the antigen. We are aware that due to the experimental nature of this work, it is unlikely that the eMigrasome platform will be used to generate mainstream preventive vaccines in the foreseeable future. However, there is a very real possibility of developing eMigrasomes into therapeutic vaccines against cancer or other diseases with unmet medical needs, or into preventive vaccines against pathogens for which the current vaccine platforms do not work. Our investigation regarding the biophysical and cellular mechanisms of eMigrasome formation makes it possible for further optimizing eMigrasome generation in a rational manner.</p><p>In this study, we demonstrate that eMigrasomes can be an effective vaccine platform. In addition, we speculate that eMigrasomes may also emerge as a versatile delivery system for a range of applications. The high rigidity and self-repair capacity of migrasomes, which is caused by enrichment of tetraspanins and cholesterol, makes migrasomes highly stable, and thus suitable as delivery carriers in various in vivo settings. More importantly, the physiological roles of migrasomes indicate that they have naturally evolved as carriers for delivering materials and information in vivo. Our previous work showed that during embryonic development, migrasomes, which are highly enriched with signaling molecules, such as chemokines, growth factors, and morphogens, are deposited at various spatially defined locations, where they act as sustained-release capsules to liberate the signaling molecules. In this way, migrasomes affect multiple aspects of embryonic development, including organ morphogenesis and angiogenesis (<xref ref-type="bibr" rid="bib17">Jiang et al., 2019</xref>; <xref ref-type="bibr" rid="bib31">Zhang et al., 2022</xref>). Additionally, in cultured fibroblast cells, migrasomes are enriched with a selected set of full-length, translationally competent mRNAs. When these mRNA-enriched migrasomes are taken up by neighboring cells, the mRNA can escape the endo-lysosome system of recipient cells and be translated into protein, thus modifying the behaviors of the recipient cells (<xref ref-type="bibr" rid="bib32">Zhu et al., 2021</xref>). Finally, in cells experiencing mild mitochondrial damage, the damaged mitochondria can be selectively transported into migrasomes and then evicted from the cell in a process named mitocytosis (<xref ref-type="bibr" rid="bib18">Jiao et al., 2021</xref>). In summary, multiple types of cargos, including materials and information, can be enriched in migrasomes under different settings, and migrasomes can be deposited at spatially defined locations in diverse biological settings to affect a broad range of biological processes, including cell-cell communication. Since eMigrasomes capture certain key features of migrasomes, it is our speculation that we may be able to develop eMigrasomes into a delivery system for diverse cargo types including nucleic acids, proteins, small molecules, and even organelles.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagent type (species) or resource</th><th align="left" valign="top">Designation</th><th align="left" valign="top">Source or reference</th><th align="left" valign="top">Identifiers</th><th align="left" valign="top">Additional information</th></tr></thead><tbody><tr><td align="left" valign="top">Cell line (<italic>Rattus norvegicus</italic>)</td><td align="left" valign="top">NRK</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">CRL-6509</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="top">HEK 293T</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">CRL-3216</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="top">MCA-205</td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top">STR profiling, authenticated by Procell Life Science &amp; Technology</td></tr><tr><td align="left" valign="top">Cell line (<italic>Cercopithecus aethiops</italic>)</td><td align="left" valign="top">Vero</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">CCL-81</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">ADSC</td><td align="left" valign="top">Procell</td><td align="left" valign="top">CP-H202</td><td align="left" valign="top">Human Adipose-derived Mesenchymal Stem Cells</td></tr><tr><td align="left" valign="top">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="top">BMSC</td><td align="left" valign="top">Procell</td><td align="left" valign="top">CP-H166</td><td align="left" valign="top">Human Bone Marrow Mesenchymal Stem Cells</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-ovalbumin (mouse monoclonal)</td><td align="left" valign="top">Santa Cruz</td><td align="left" valign="top">sc-80589</td><td align="left" valign="top">ELISA (1:4000– 1:512,000), WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-Spike (mouse monoclonal)</td><td align="left" valign="top">Sino Biological</td><td align="left" valign="top">40591-MM42</td><td align="left" valign="top">ELISA (1:5000– 1:640,000), WB (1:1000)</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-Spike (chimeric MAb)</td><td align="left" valign="top">Sino Biological</td><td align="left" valign="top">40150-D001</td><td align="left" valign="top">IF (1:100)</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pB-mOVA-mCherry (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">pB-mCherry derived plasmid</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pB-S-mCherry (plasmid)</td><td align="left" valign="top">This paper</td><td align="left" valign="top"/><td align="left" valign="top">pB-mCherry derived plasmid</td></tr><tr><td align="left" valign="top">Recombinant DNA reagent</td><td align="left" valign="top">pB-Tspan4-GFP (plasmid)</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib18">Jiao et al., 2021</xref></td><td align="left" valign="top"/><td align="left" valign="top">pB-GFP derived plasmid</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">Ovalbumin</td><td align="left" valign="top">Sigma</td><td align="left" valign="top">A5503</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Latrunculin A</td><td align="left" valign="top">Cayman</td><td align="left" valign="top">10010630</td><td align="left" valign="top">0.25–2 µM</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">Imject Alum</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">77161</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">Fibronectin</td><td align="left" valign="top">Sigma</td><td align="left" valign="top">F0895</td><td align="left" valign="top">10 µg/ml for imaging; 4 µg/ml for eMigrasome preparation</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">40 kDa Dextran-TMR</td><td align="left" valign="top">Thermo Fisher</td><td align="left" valign="top">D1842</td><td align="left" valign="top">(25 μg/ml)</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Molecular cloning</title><p>For the construction of pB-Tspan4-GFP, pB-PD1-mCherry, pB-S-mCherry, pmCherry-N1-Tspan4, pmCherry-N1-CD82, and pmCherry-N1-Tspan1, the coding sequence of the corresponding genes was amplified by PCR and subsequently inserted into the vector using a One Step Cloning Kit (Vazyme, C112). For the construction of pB-mOVA-mCherry, the sequence spanning amino acids 252–289 of syntatin-2 (STX-2), which incorporates the transmembrane domain along with the polybasic tail, was amplified from mouse cDNA by polymerase chain reaction (NEB, M0492L) using primers below:</p><list list-type="simple" id="list1"><list-item><p>fwd: 5’-<named-content content-type="sequence">atgaagaaagccatcaaataccagagc</named-content>-3’;</p></list-item><list-item><p>rev: 5’-<named-content content-type="sequence">gcaccgatggagcccatcgagcctttgccaaccgacaagccaatg</named-content>-3’.</p></list-item></list><p>The sequence of OVA was amplified from the plasmid using primers below:</p><list list-type="simple" id="list2"><list-item><p>fwd: 5’-<named-content content-type="sequence">atgggctccatcggtgc</named-content>-3’;</p></list-item><list-item><p>rev: 5’-<named-content content-type="sequence">aggggaaacacatctgccaaag</named-content>-3’.</p></list-item></list><p>Using STX2<sub>252-289</sub> and OVA as templates, the membrane-tethered mOVA, in which STX2<sub>252-289</sub> sequence is tagged to OVA sequence, was further amplified using the primers below:</p><list list-type="simple" id="list3"><list-item><p>fwd: 5’-<named-content content-type="sequence">tcagatctcgagctcaagcttatgaagaaagccatcaaataccagagc</named-content>-3’</p></list-item><list-item><p>rev: 5’-<named-content content-type="sequence">tggtggcgaccggtggatcccggaggaagaacactaaggcagcaaaagagaag</named-content>-3’</p></list-item></list><p>The fragment was inserted into pmCherry-N1 vector using a One Step Cloning Kit (Vazyme, C112).</p></sec><sec id="s4-2"><title>Cell culture</title><p>Cell lines used in this study include NRK (ATCC CRL-6509), HEK 293T (ATCC CRL-3216), MCA-205 (STR profiling, authenticated by Procell Life Science &amp; Technology), Vero (ATCC CCL-81), ADSC (Procell CP-H202), and BMSC (Procell CP-H166). All the cell lines were routinely tested for mycoplasma, and only when tested negative were used for the experiments. No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC.</p><p>Cells were cultured at 37°C with 5% CO<sub>2</sub>. NRK cells and HEK 293T cells were grown in DMEM (Gibco, C11995500BT) supplemented with 10% (v/v) FBS (Biological Industries), 1% (v/v) GlutaMAX (Gibco, 35050-061), and 1% (v/v) penicillin–streptomycin. MCA-205 cells were grown in RPMI 1640 (Gibco, C11875500BT) supplemented with 10% (v/v) FBS, 1% (v/v) GlutaMAX, and 1% (v/v) penicillin–streptomycin. Vero-TMPRSS2 cells were maintained in DMEM supplemented with 10% (v/v) FBS and 50 IU/ml penicillin–streptomycin. ADSC cells and BMSC cells were grown in stem cell serum-free medium (CytoNiche, RMZ112).</p></sec><sec id="s4-3"><title>Cell transfection and cell line development</title><p>For NRK cells, transfection was performed using electroporation (AMAXA, Nucleofector). For MCA-205 cells, transfection was performed using Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific, L3000015). In establishing stable cell lines, the transfected cells underwent initial selection with Hygromycin B (Roche, 10843555001) and were subsequently sorted into single colonies in 96-well plates via flow cytometry.</p></sec><sec id="s4-4"><title>Imaging</title><p>Confocal imaging of live cells and isolated eMigrasomes was performed using a Nikon A1HD25 laser scanning confocal microscope. Cells were cultured in a confocal chamber (Cellvis, D35-20-1-N or D35C4-20-1.5-N) that had been pre-treated with 10 μg/ml fibronectin (F0895) and allowed to proliferate overnight (14–18 hours). For visualizing eMigrasomes, a small region in the confocal chamber was coated with a 10 μl drop of 10 μg/ml fibronectin. Following aspiration of the fibronectin, a 10 μl drop of isolated eMigrasomes was dispensed into the coated area and left to settle for a minimum of 1 hour prior to imaging. To prevent evaporation, the chamber was sealed using parafilm. For immunofluoresence assay, eMigrasomes were settled at 4°C overnight and then fixed by 2% PFA. Nonspecific binding was blocked by incubating with 10% (v/v) FBS. eMigrasomes were then stained with a spike primary antibody (40150-D001, SinoBiological) for 1 hour at RT, triple washed with PBS, and then stained with AlexaFluor647-conjugated secondary antibody. Samples were triple washed with PBS before imaging.</p></sec><sec id="s4-5"><title>Real-time hypotonic stimulation</title><p>To observe the dynamics of migrasome-like structures and eMigrasomes, a custom-made buffer displacement device was utilized (refer to <xref ref-type="fig" rid="fig1">Figure 1D</xref>). Essentially, three apertures were created on the lid of a confocal chamber to perfectly accommodate a silicon microinjection tube with an external diameter of 1.9 mm. The silicon microinjection tube was securely connected to a 1 ml syringe after the removal of its sharp needle.</p><p>For a single-step stimulation process, two syringes were employed. One was kept empty, while the other was filled with the desired hypotonic buffer. During time-lapse imaging, the reservoir solution was aspirated using the empty syringe, and the hypotonic buffer was simultaneously injected from the other syringe.</p><p>In the case of stepwise stimulation, three syringes were deployed. The first was loaded with the initial buffer from the reservoir and was used to withdraw the reservoir solution. The second syringe contained deionized water (ddH<sub>2</sub>O) and was used to add a specific volume of water at each step. The third syringe, which was empty, was used to ensure thorough mixing of the reservoir solution after each stimulation event.</p></sec><sec id="s4-6"><title>Drug treatment</title><p>For SMS2 inhibition, 30 minutes post seeding of the cells, the culture medium was gently replaced with fresh medium containing either 25 μM SMS2-IN-1 (MCE, HY-102041) or 0.25 (v/v) % DMSO. Cells were treated for 16 hours prior to imaging.</p><p>For cholesterol extraction from in situ or isolated eMigrasomes, h-KDPBS containing 10 mM MβCD (Sigma, 332615) or 10 (v/v) % ddH<sub>2</sub>O was applied. For in situ eMigrasomes, z-stack images were collected after 30 minutes incubation at 37°C. For isolated eMigrasomes, buffer containing MβCD or ddH<sub>2</sub>O was applied using the real-time stimulation device described above. A 20-minute time-lapse imaging session was performed to capture the process of morphological changes in eMigrasomes.</p></sec><sec id="s4-7"><title>Permeability assay</title><p>Isolated eMigrasomes were diluted in h-KPBS-BSA, containing 5 μg/ml of Cy5 and 25 μg/ml of 40 kDa Dextran-TMR (D1842). A droplet of the eMigrasome solution was prepared and imaged following the procedure described previously.</p></sec><sec id="s4-8"><title>Ion replacement assay</title><p>The standard formulation of DPBS is 138 mM NaCl, 8.1 mM Na<sub>2</sub>HPO<sub>4</sub>, 2.7 mM KCl, 1.5 mM KH<sub>2</sub>PO<sub>4</sub>. In the ion replacement assay, as referenced in <xref ref-type="fig" rid="fig1">Figure 1L and M</xref>, the 138 mM NaCl in DPBS was substituted with equal molar KCl or CsCl. The other three components were not changed.</p><p>The K-DPBS formulation utilized for eMigrasome production contains 140.6 mM KCl, 1.5 mM KH<sub>2</sub>PO<sub>4</sub>, 8.1 mM K<sub>2</sub>HPO<sub>4</sub>.</p></sec><sec id="s4-9"><title>Induction and purification of eMigrasomes</title><p>It is important to underscore that several critical parameters, such as the seeding density, the working concentration of LatA, and the incubation period, along with the hypotonic gradient, should be individually optimized for each cell type. The quantities of cells and reagents utilized should be modulated according to the flask size (examples are provided in the following table).</p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Cell type</th><th align="left" valign="top">NRK</th><th align="left" valign="top">MCA-205</th><th align="left" valign="top">ADCS</th><th align="left" valign="top">BMSC</th></tr></thead><tbody><tr><td align="left" valign="top">Seeding density (cells/cm<sup>2</sup>)</td><td align="left" valign="top">1.5 × 10<sup>4</sup></td><td align="left" valign="top">3 × 10<sup>4</sup></td><td align="left" valign="top">2 × 10<sup>4</sup></td><td align="left" valign="top">2 × 10<sup>4</sup></td></tr><tr><td align="left" valign="top">Latrunculin A concentration (μM)</td><td align="left" valign="top">2</td><td align="left" valign="top">2</td><td align="left" valign="top">0.6</td><td align="left" valign="top">0.6</td></tr><tr><td align="left" valign="top">Latrunculin A incubation time (minutes)</td><td align="left" valign="top">10</td><td align="left" valign="top">45</td><td align="left" valign="top">20</td><td align="left" valign="top">20</td></tr><tr><td align="left" valign="top">Reduced osmolarity per step</td><td align="left" valign="top">1/6</td><td align="left" valign="top">1/4</td><td align="left" valign="top">1/6</td><td align="left" valign="top">1/6</td></tr></tbody></table></table-wrap><p>In the following method, the purification of eMigrasomes from NRK cells cultured in a single T75 flask (NEST, 708003) is used as a representative example. Three major steps include cell preparation, eMigrasome induction, and purification.</p><sec id="s4-9-1"><title>Cell preparation</title><p>A T75 flask was coated with 4 μg/ml of fibronectin. 1 × 10<sup>6</sup> cells were seeded into the pre-coated flask, allowed to grow for 14–16 hours.</p></sec><sec id="s4-9-2"><title>eMigrasome induction</title><p>Cortical actin disruption was achieved by discarding the culture medium and rinsing the cells once with PBS. Then, 7.5 ml of K-DPBS containing 2 μM of LatA was added to the flask. The cells were incubated at 37°C in a 5% CO<sub>2</sub> atmosphere for 10 minutes.</p><p>Hypotonic stimulation was performed by placing the flask on an orbital shaker inside the CO<sub>2</sub> incubator and adjusting the speed to 40 rpm. The stimulation was progressively introduced by adding 1.5, 1.8, or 2.2 ml of deionized water at 3-minute intervals. Following this, the speed of the orbital shaker was increased to 60 rpm for 5 minutes.</p></sec><sec id="s4-9-3"><title>eMigrasome purification</title><p>First, the bubbles were harvested using the following procedure. The supernatant containing cell bodies was discarded. The flask’s bottom was gently washed once with hK-DPBS (60% K-DPBS matching the current osmolarity). Subsequently, 4 ml of hK-DPBS-BSA (60% K-DPBS containing 1 mg/ml BSA) was added to the flask. Gentle pipetting was employed to detach the eMigrasomes, and the resultant solution was collected into a conical tube. This step was repeated once, and the collected solutions were combined.</p><p>To remove the remaining cell bodies, a process of differential centrifugation and gravity-dependent filtration was used. Initially, the solution was centrifuged at 300 × <italic>g</italic> at 4°C for 10 minutes, after which the supernatant was collected. The same process was repeated at 500 × <italic>g</italic> for 10 minutes. The collected supernatant was poured into a filter cup containing a pre-rinsed 6 μm parylene filter (Hangzhou Branemagic Medical Technology, F-PAC007). The filter was pre-rinsed with 100% ethanol followed by hK-DPBS-BSA. The flow-through was then collected in a low-protein-binding conical tube (Eppendorf, 0030122240).</p><p>To concentrate the eMigrasomes, the solution was centrifuged at 20,000 × <italic>g</italic> at 4°C for 30 minutes. In the event of a large volume, a longer time may be necessary. The supernatant was discarded, and the eMigrasome pellet was resuspended in PBS. The protein concentration was determined using a BCA analysis, and the PBS volume was adjusted to reach the desired eMigrasome concentration. For long-term storage, it was recommended that the eMigrasomes were stored as a pellet, with a small volume of hK-DPBS-BSA to cover it. This measure was adopted to minimize eMigrasome loss due to container adsorption.</p></sec></sec><sec id="s4-10"><title>Negative staining TEM</title><p>Isolated eMigrasomes underwent fixation by the addition of an equal volume of 2.5% glutaraldehyde (GA). A droplet of the fixed eMigrasome sample was deposited onto a copper grid for 15 minutes. Excess sample was blotted off with filter paper. The grid was promptly washed with a droplet of double distilled water (ddH<sub>2</sub>O), stained with 1% uranyl acid for 1 minute, and then further washed with two droplets of ddH<sub>2</sub>O. Remaining water was blotted off using filter paper and the grid was allowed to air-dry fully before imaging was conducted via transmission electron microscopy (TEM).</p></sec><sec id="s4-11"><title>Cryo-EM sample preparation and image acquisition</title><p>Quantifoil Cu grids (200 mesh, R2/2) underwent glow-discharging using a plasma cleaning device (PDC-32G, Harrick Plasma). Each EM grid was applied with 4 µl sample and vitrified by plugging into liquid ethane using the Vitrobot Mark IV system (Thermo Fisher Scientific). The cryo-EM samples were examined using an FEI Tecnai Arctica 200 kV transmission electron microscope, and images were captured at a magnification of 23.5 kx using an FEI Falcon II direct electron detector, with a dose approximately around 15 e−Å−2.</p></sec><sec id="s4-12"><title>eMigrasome quantification using flow cytometry</title><p>Isolated eMigrasomes were suspended in h-KDPBS containing 1 μg/ml Wheat Germ Agglutinin (WGA, Thermo, W11262). Various dilutions were prepared to ensure at least one dilution had a concentration ranging from 1000–10,000 eMigrasomes per μl. Data were collected using a CytoFlex LX cytometer (Beckman). The threshold for forward scatter (FSC) was manually set to 4000 to detect small particles. Events that were double positive for B525-FITC and Y610-mCherry were gated as eMigrasomes.</p></sec><sec id="s4-13"><title>Size analysis by Hough circle transforming</title><p>Size analysis of isolated eMigrasomes was conducted using ImageJ, complemented by the Hough circle transform plugin. Sum slices processing of Z-stack was applied to the 488 channel of the confocal images, representing the fluorescence signal from Tspan4-GFP. The image was subsequently converted to an 8-bit grayscale. Edge detection was performed using the ‘Find Edges’ function to identify individual eMigrasomes. Subsequently, the ‘Threshold’ function was applied to encompass the majority of the fluorescent signal from the eMigrasomes. Hough circle transform analysis was then utilized with the following parameters: easy mode; minimum = 3 pixels; maximum = 24 pixels; Hough score threshold = 0.9. All output options were selected.</p></sec><sec id="s4-14"><title>Immunoblotting</title><p>Cells or eMigrasomes were subjected to lysis using a 2% SDS solution in 50 mM Tris buffer, followed by heating at 95°C. The protein concentration of the samples was assessed using a BCA kit (Vazyme, E112-02-AB). The lysates were diluted to the desired concentration and then denatured via the addition of loading buffer (Beyotime, P0015). The proteins were segregated by SDS-PAGE electrophoresis (Epizyme, PG112, or Yeasen, 36255ES10), and subsequently transferred to a 0.45 μm PVDF membrane (Millipore, IPVH00010) in accordance with a standard protocol. The blot was blocked with 5% milk in TBST and left to incubate overnight with the primary antibody at 4°C. The blot was then washed thrice with TBST and incubated with the secondary antibody at RT for 1 hour. Finally, the blot underwent three more washes prior to signal detection via chemiluminescence imaging (CYANAGEN, XLS070P, or Thermo, 34075), utilizing a ChemiDoc MP Imaging System (Bio-Rad).</p><p>Primary antibodies used for immunoblotting included anti-integrin α5 (CST, 4705T), anti-Na-K-ATPase (CST, 3010S), anti-histone H3 (CST, 4499S), anti-lamp2 (Sigma), anti-calnexin (abcam, ab22595), anti-GFP (Roche, 11814460001 or abcam, ab290), anti-GAPDH (Proteintech, 60004-1-Ig), anti-TIM23 (BD, 611222), anti-S1 (Sinobio, 40591-MM42), anti-OVA (Santa Cruz, sc80587 or abcam, ab181688), and anti-mCherry (abcam, ab125096). Primary antibodies were diluted using Solution 1 (Takara, NKB-101). Secondary antibodies used for immunoblotting included peroxidase AffiniPure goat anti-rabbit IgG (H+L) (Jackson ImmunoResearch, 111-035-003) and peroxidase AffiniPure goat anti-mouse IgG (H+L) (Jackson ImmunoResearch,115-035-003). Secondary antibodies were diluted using 5% milk in TBST.</p></sec><sec id="s4-15"><title>Mice</title><p>WT C57BL/6 (Jax 000664) specific-pathogen-free (SPF) mice were procured from the Laboratory Animal Center of Tsinghua University, China. The OT-II (Jax 004194) mice were donated by Dr. Yan Shi. All the mice were bred and maintained under SPF conditions at the Laboratory Animal Center of Tsinghua University, in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Tsinghua University (protocol #22-LZH1). For sample size determination, the number of mice was rationally determined based on the known effect size.</p></sec><sec id="s4-16"><title>Immunization</title><p>For systemic immunization, mice were intravenously administered eM-OVA dissolved in 100 µl PBS, or intraperitoneally administered a mixture containing 50 μg OVA in 50 μL PBS (Sigma; A5503) and 50 μl Imject Alum (Thermo; 77161). For nasal immunization, mice were anesthetized using isoflurane and subsequently intranasally administered 20 μg eM-OVA dissolved in 30 μl PBS. For subcutaneous immunization, 20 μg eM-OVA in 100 µl PBS was administered through injections on both sides of the buttock.</p></sec><sec id="s4-17"><title>Enzyme-linked immunosorbent assay (ELISA)</title><p>Serum was prepared from whole blood by centrifugation. The levels of antigen-specific antibody were determined using a direct ELISA method. Briefly, a 96-well plate was coated overnight at 4°C with antigen (2 μg/ml). The wells were then blocked with PBS containing 10% fetal calf serum before the addition of serially diluted serum. Horseradish peroxidase-conjugated secondary antibodies were incubated for 1 hour at RT. Between each step, wells were washed with PBST. The colorimetric reaction was carried out using the 1-Step Ultra TMB-ELISA Substrate. The reaction was stopped with 2 N H<sub>2</sub>SO<sub>4</sub>, and absorbance at 450 nm was read using a multimode reader. For quantification of OVA-IgG and Spike-IgG, a standard curve was generated using serially diluted anti-OVA antibody (Santa Cruz; sc-80589) and anti-Spike antibody (Sino Biological; 40591-MM42), respectively.</p></sec><sec id="s4-18"><title>Fluorescence-based neutralization test</title><p>Mouse sera were heat-inactivated at 56°C for a duration of 30 minutes. The indicated dilutions of samples were mixed with 2 × 10<sup>2</sup> FFU (focus-forming units) of VSV-Venus-SARS-CoV-2 and incubated for 1 hour at a temperature of 37°C. The mixture of serum and virus was then added to Vero-TMPRSS2 cells grown on 96-well plates and incubated at 37°C for about 40 hours. The cells were then harvested and fixed in a 4% paraformaldehyde solution for 20 minutes at RT. The fixed cells were resuspended in PBS and analyzed using a LSRFortessa SORP (BD Biosciences) and FlowJo software.</p><p>The Vero-TMPRSS2 cell line, which was constructed based on Vero (ATCC CCL-81), stably expressed the TMPRSS2 (Transmembrane Serine Protease 2) protein to enhance the entry of the SARS-CoV-2 spike.</p></sec><sec id="s4-19"><title>Statistics</title><p>All data were subjected to analysis using GraphPad Prism statistical software. Unpaired two-tailed <italic>t</italic>-tests or paired two-tailed <italic>t</italic>-tests were employed for the data analysis. The results are represented as the mean ± SD. A <italic>P</italic> value of &lt;0.05 was deemed to indicate statistical significance. At least two biological replicates were performed for all the experiments in this study.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>is one of the inventors on relevant patent applications (Patent No.: US 12221631 B2) held by Migrasome Therapeutics</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>employee of Migrasome Therapeutics</p></fn><fn fn-type="COI-statement" id="conf4"><p>is the scientific founder of Migrasome Therapeutics</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Supervision, Methodology</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All the mice were bred and maintained under SPF conditions at the Laboratory Animal Center of Tsinghua University, in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Tsinghua University (Protocol #22-LZH1).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-97621-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript, figures, figure supplements, and source data files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This research was supported by the Ministry of Science and Technology of the People’s Republic of China (grant no. 2024YFA1307301 to LY), Tsinghua-Toyota Joint Research Fund (grant no. 20233930058 to LY), Tsinghua University Dushi Program (grant no. 20251080019 to LY), the National Natural Science Foundation of China (grant nos. 32030023, 92354306, and 32330025 to LY, 82530021 to ZL), and Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (grant no.CI2023C024YL to LY). Sincere gratitude is expressed to Baidong Hou (Institute of Biophysics, Chinese Academy of Sciences) for providing mouse strains and engaging in valuable discussions. We thank the State Key Laboratory of Membrane Biology, SLSTU-Nikon Biological Imaging Center, Laboratory of Animal Resources Center (THU-LARC), Tsinghua University, for technical support. We also acknowledge the Research Fund of the Vanke School of Public Health at Tsinghua University.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baden</surname><given-names>LR</given-names></name><name><surname>El Sahly</surname><given-names>HM</given-names></name><name><surname>Essink</surname><given-names>B</given-names></name><name><surname>Kotloff</surname><given-names>K</given-names></name><name><surname>Frey</surname><given-names>S</given-names></name><name><surname>Novak</surname><given-names>R</given-names></name><name><surname>Diemert</surname><given-names>D</given-names></name><name><surname>Spector</surname><given-names>SA</given-names></name><name><surname>Rouphael</surname><given-names>N</given-names></name><name><surname>Creech</surname><given-names>CB</given-names></name><name><surname>McGettigan</surname><given-names>J</given-names></name><name><surname>Khetan</surname><given-names>S</given-names></name><name><surname>Segall</surname><given-names>N</given-names></name><name><surname>Solis</surname><given-names>J</given-names></name><name><surname>Brosz</surname><given-names>A</given-names></name><name><surname>Fierro</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>H</given-names></name><name><surname>Neuzil</surname><given-names>K</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Gilbert</surname><given-names>P</given-names></name><name><surname>Janes</surname><given-names>H</given-names></name><name><surname>Follmann</surname><given-names>D</given-names></name><name><surname>Marovich</surname><given-names>M</given-names></name><name><surname>Mascola</surname><given-names>J</given-names></name><name><surname>Polakowski</surname><given-names>L</given-names></name><name><surname>Ledgerwood</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Bennett</surname><given-names>H</given-names></name><name><surname>Pajon</surname><given-names>R</given-names></name><name><surname>Knightly</surname><given-names>C</given-names></name><name><surname>Leav</surname><given-names>B</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Ivarsson</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Zaks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title><source>New England Journal of Medicine</source><volume>384</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>JB</given-names></name><name><surname>Rothlauf</surname><given-names>PW</given-names></name><name><surname>Chen</surname><given-names>RE</given-names></name><name><surname>Kafai</surname><given-names>NM</given-names></name><name><surname>Fox</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>BK</given-names></name><name><surname>Shrihari</surname><given-names>S</given-names></name><name><surname>McCune</surname><given-names>BT</given-names></name><name><surname>Harvey</surname><given-names>IB</given-names></name><name><surname>Keeler</surname><given-names>SP</given-names></name><name><surname>Bloyet</surname><given-names>LM</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>LJ</given-names></name><name><surname>Winkler</surname><given-names>ES</given-names></name><name><surname>Holtzman</surname><given-names>MJ</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name><name><surname>Whelan</surname><given-names>SPJ</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice</article-title><source>Cell Host &amp; Microbe</source><volume>28</volume><fpage>465</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.07.018</pub-id><pub-id pub-id-type="pmid">32798445</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>JB</given-names></name><name><surname>Rothlauf</surname><given-names>PW</given-names></name><name><surname>Chen</surname><given-names>RE</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>AS</given-names></name><name><surname>Bloyet</surname><given-names>LM</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Tahan</surname><given-names>S</given-names></name><name><surname>Droit</surname><given-names>L</given-names></name><name><surname>Ilagan</surname><given-names>M</given-names></name><name><surname>Tartell</surname><given-names>MA</given-names></name><name><surname>Amarasinghe</surname><given-names>G</given-names></name><name><surname>Henderson</surname><given-names>JP</given-names></name><name><surname>Miersch</surname><given-names>S</given-names></name><name><surname>Ustav</surname><given-names>M</given-names></name><name><surname>Sidhu</surname><given-names>S</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Theel</surname><given-names>ES</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Whelan</surname><given-names>SPJ</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2</article-title><source>Cell Host &amp; Microbe</source><volume>28</volume><fpage>475</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.06.021</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charrin</surname><given-names>S</given-names></name><name><surname>Le Naour</surname><given-names>F</given-names></name><name><surname>Labas</surname><given-names>V</given-names></name><name><surname>Billard</surname><given-names>M</given-names></name><name><surname>Le Caer</surname><given-names>J-P</given-names></name><name><surname>Emile</surname><given-names>J-F</given-names></name><name><surname>Petit</surname><given-names>M-A</given-names></name><name><surname>Boucheix</surname><given-names>C</given-names></name><name><surname>Rubinstein</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells</article-title><source>Biochemical Journal</source><volume>373</volume><fpage>409</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1042/bj20030343</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>WGA is a probe for migrasomes</article-title><source>Cell Discovery</source><volume>5</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1038/s41421-018-0078-2</pub-id><pub-id pub-id-type="pmid">30820350</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>KL</given-names></name><name><surname>Zeng</surname><given-names>ZM</given-names></name><name><surname>Langford</surname><given-names>AL</given-names></name><name><surname>Bowen</surname><given-names>SM</given-names></name><name><surname>Todd</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>PGRL is a major CD81-associated protein on lymphocytes and distinguishes a new family of cell surface proteins</article-title><source>Journal of Immunology</source><volume>167</volume><fpage>5115</fpage><lpage>5121</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.9.5115</pub-id><pub-id pub-id-type="pmid">11673522</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comoy</surname><given-names>EE</given-names></name><name><surname>Capron</surname><given-names>A</given-names></name><name><surname>Thyphronitis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>In vivo induction of type 1 and 2 immune responses against protein antigens</article-title><source>International Immunology</source><volume>9</volume><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1093/intimm/9.4.523</pub-id><pub-id pub-id-type="pmid">9138012</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crommelin</surname><given-names>DJA</given-names></name><name><surname>Anchordoquy</surname><given-names>TJ</given-names></name><name><surname>Volkin</surname><given-names>DB</given-names></name><name><surname>Jiskoot</surname><given-names>W</given-names></name><name><surname>Mastrobattista</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Addressing the cold reality of mRNA vaccine stability</article-title><source>Journal of Pharmaceutical Sciences</source><volume>110</volume><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2020.12.006</pub-id><pub-id pub-id-type="pmid">33321139</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dharan</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Cheppali</surname><given-names>SK</given-names></name><name><surname>Goren</surname><given-names>S</given-names></name><name><surname>Shendrik</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Kozlov</surname><given-names>MM</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Sorkin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Tetraspanin 4 stabilizes membrane swellings and facilitates their maturation into migrasomes</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>1037</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-36596-9</pub-id><pub-id pub-id-type="pmid">36823145</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>T</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The phosphatidylinositol (4,5)-bisphosphate-Rab35 axis regulates migrasome formation</article-title><source>Cell Research</source><volume>33</volume><fpage>617</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1038/s41422-023-00811-5</pub-id><pub-id pub-id-type="pmid">37142675</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grau</surname><given-names>S</given-names></name><name><surname>Ferrández</surname><given-names>O</given-names></name><name><surname>Martín-García</surname><given-names>E</given-names></name><name><surname>Maldonado</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reconstituted mRNA COVID-19 vaccines may maintain stability after continuous movement</article-title><source>Clinical Microbiology and Infection</source><volume>27</volume><elocation-id>1698</elocation-id><pub-id pub-id-type="doi">10.1016/j.cmi.2021.06.007</pub-id><pub-id pub-id-type="pmid">34129908</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Lou</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial</article-title><source>Life Metabolism</source><volume>2</volume><elocation-id>load019</elocation-id><pub-id pub-id-type="doi">10.1093/lifemeta/load019</pub-id><pub-id pub-id-type="pmid">39872015</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>EK</given-names></name><name><surname>Lambert</surname><given-names>IH</given-names></name><name><surname>Pedersen</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Physiology of cell volume regulation in vertebrates</article-title><source>Physiological Reviews</source><volume>89</volume><fpage>193</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1152/physrev.00037.2007</pub-id><pub-id pub-id-type="pmid">19126758</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogenesch</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mechanism of immunopotentiation and safety of aluminum adjuvants</article-title><source>Frontiers in Immunology</source><volume>3</volume><elocation-id>406</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2012.00406</pub-id><pub-id pub-id-type="pmid">23335921</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zucker</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Elias</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Kozlov</surname><given-names>MM</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Migrasome formation is mediated by assembly of micron-scale tetraspanin macrodomains</article-title><source>Nature Cell Biology</source><volume>21</volume><fpage>991</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0367-5</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>HW</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Assembly of Tetraspanin-enriched macrodomains contains membrane damage to facilitate repair</article-title><source>Nature Cell Biology</source><volume>24</volume><fpage>825</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1038/s41556-022-00920-0</pub-id><pub-id pub-id-type="pmid">35654840</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Migrasomes provide regional cues for organ morphogenesis during zebrafish gastrulation</article-title><source>Nature Cell Biology</source><volume>21</volume><fpage>966</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0358-6</pub-id><pub-id pub-id-type="pmid">31371827</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sho</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>YT</given-names></name><name><surname>Wei</surname><given-names>YH</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mitocytosis, a migrasome-mediated mitochondrial quality-control process</article-title><source>Cell</source><volume>184</volume><fpage>2896</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.04.027</pub-id><pub-id pub-id-type="pmid">34048705</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lefranc</surname><given-names>MP</given-names></name><name><surname>Lefranc</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2001">2001</year><source>The Immunoglobulin FactsBook</source><publisher-name>Gulf Professional Publishing</publisher-name><pub-id pub-id-type="doi">10.1016/B978-012441352-8/50008-4</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>S</given-names></name><name><surname>Shoham</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The tetraspanin web modulates immune-signalling complexes</article-title><source>Nature Reviews. Immunology</source><volume>5</volume><fpage>136</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/nri1548</pub-id><pub-id pub-id-type="pmid">15688041</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Bacterial toxins induce non-canonical migracytosis to aggravate acute inflammation</article-title><source>Cell Discovery</source><volume>10</volume><elocation-id>112</elocation-id><pub-id pub-id-type="doi">10.1038/s41421-024-00729-1</pub-id><pub-id pub-id-type="pmid">39500876</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration</article-title><source>Cell Research</source><volume>25</volume><fpage>24</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/cr.2014.135</pub-id><pub-id pub-id-type="pmid">25342562</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>RM</given-names></name><name><surname>Brady</surname><given-names>JL</given-names></name><name><surname>Lew</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice</article-title><source>Journal of Immunological Methods</source><volume>212</volume><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/s0022-1759(98)00015-5</pub-id><pub-id pub-id-type="pmid">9672206</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Lagniton</surname><given-names>PNP</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>mRNA vaccines for COVID-19: what, why and how</article-title><source>International Journal of Biological Sciences</source><volume>17</volume><fpage>1446</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.7150/ijbs.59233</pub-id><pub-id pub-id-type="pmid">33907508</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polack</surname><given-names>FP</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Absalon</surname><given-names>J</given-names></name><name><surname>Gurtman</surname><given-names>A</given-names></name><name><surname>Lockhart</surname><given-names>S</given-names></name><name><surname>Perez</surname><given-names>JL</given-names></name><name><surname>Pérez Marc</surname><given-names>G</given-names></name><name><surname>Moreira</surname><given-names>ED</given-names></name><name><surname>Zerbini</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>R</given-names></name><name><surname>Swanson</surname><given-names>KA</given-names></name><name><surname>Roychoudhury</surname><given-names>S</given-names></name><name><surname>Koury</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Kalina</surname><given-names>WV</given-names></name><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>Frenck</surname><given-names>RW</given-names><suffix>Jr</suffix></name><name><surname>Hammitt</surname><given-names>LL</given-names></name><name><surname>Türeci</surname><given-names>Ö</given-names></name><name><surname>Nell</surname><given-names>H</given-names></name><name><surname>Schaefer</surname><given-names>A</given-names></name><name><surname>Ünal</surname><given-names>S</given-names></name><name><surname>Tresnan</surname><given-names>DB</given-names></name><name><surname>Mather</surname><given-names>S</given-names></name><name><surname>Dormitzer</surname><given-names>PR</given-names></name><name><surname>Şahin</surname><given-names>U</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><name><surname>Gruber</surname><given-names>WC</given-names></name><collab>C4591001 Clinical Trial Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Z</given-names></name><name><surname>Dubin</surname><given-names>AE</given-names></name><name><surname>Mathur</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>B</given-names></name><name><surname>Reddy</surname><given-names>K</given-names></name><name><surname>Miraglia</surname><given-names>LJ</given-names></name><name><surname>Reinhardt</surname><given-names>J</given-names></name><name><surname>Orth</surname><given-names>AP</given-names></name><name><surname>Patapoutian</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>SWELL1, a plasma membrane protein, is an essential component of volume-regulated anion channel</article-title><source>Cell</source><volume>157</volume><fpage>447</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.03.024</pub-id><pub-id pub-id-type="pmid">24725410</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidarsson</surname><given-names>G</given-names></name><name><surname>Dekkers</surname><given-names>G</given-names></name><name><surname>Rispens</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>IgG subclasses and allotypes: from structure to effector functions</article-title><source>Frontiers in Immunology</source><volume>5</volume><elocation-id>520</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00520</pub-id><pub-id pub-id-type="pmid">25368619</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname><given-names>FK</given-names></name><name><surname>Ullrich</surname><given-names>F</given-names></name><name><surname>Münch</surname><given-names>J</given-names></name><name><surname>Lazarow</surname><given-names>K</given-names></name><name><surname>Lutter</surname><given-names>D</given-names></name><name><surname>Mah</surname><given-names>N</given-names></name><name><surname>Andrade-Navarro</surname><given-names>MA</given-names></name><name><surname>von Kries</surname><given-names>JP</given-names></name><name><surname>Stauber</surname><given-names>T</given-names></name><name><surname>Jentsch</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of LRRC8 heteromers as an essential component of the volume-regulated anion channel VRAC</article-title><source>Science</source><volume>344</volume><fpage>634</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1126/science.1252826</pub-id><pub-id pub-id-type="pmid">24790029</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>T</given-names></name><name><surname>Zu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pairing of integrins with ECM proteins determines migrasome formation</article-title><source>Cell Research</source><volume>27</volume><fpage>1397</fpage><lpage>1400</lpage><pub-id pub-id-type="doi">10.1038/cr.2017.108</pub-id><pub-id pub-id-type="pmid">28829047</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Kadonosono</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Okochi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Osmotic stress induces the formation of migrasome‐like vesicles</article-title><source>FEBS Letters</source><volume>598</volume><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.14816</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Monocytes deposit migrasomes to promote embryonic angiogenesis</article-title><source>Nature Cell Biology</source><volume>24</volume><fpage>1726</fpage><lpage>1738</lpage><pub-id pub-id-type="doi">10.1038/s41556-022-01026-3</pub-id><pub-id pub-id-type="pmid">36443426</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Zou</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Lateral transfer of mRNA and protein by migrasomes modifies the recipient cells</article-title><source>Cell Research</source><volume>31</volume><fpage>237</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-00415-3</pub-id><pub-id pub-id-type="pmid">32994478</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zucker</surname><given-names>B</given-names></name><name><surname>Dharan</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Sorkin</surname><given-names>R</given-names></name><name><surname>Kozlov</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Migrasome formation is initiated preferentially in tubular junctions by membrane tension</article-title><source>Biophysical Journal</source><volume>124</volume><fpage>604</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2024.12.029</pub-id><pub-id pub-id-type="pmid">39755943</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97621.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Krzych</surname><given-names>Urszula</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Walter Reed Army Institute of Research</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This study, from the group that pioneered migrasome, describes a novel vaccine platform of engineered migrosomes that behave like natural migrasomes. Importantly, this platform has the potential to overcome obstacles associated with cold chain issues for vaccines such as mRNA. In the revised version, the authors have addressed previous concerns, and the results from additional experiments provide <bold>compelling</bold> evidence that features methods, data, and analyses more rigorous than the current state-of-the-art. Although the findings are <bold>important</bold> with practical implications for the vaccine technology, results from additional experiments would make this an outstanding study.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97621.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Outstanding fundamental phenomenon (migrasomes) en route to become transitionally highly significant.</p><p>Strengths:</p><p>Innovative approach at several levels: Migrasomes, discovered by DR. Yu's group, are an outstanding biological phenomenon of fundamental interest and now of potentially practical value.</p><p>Weaknesses:</p><p>I feel that the overemphasis on practical aspects (vaccine), however important, eclipses some of the fundamental aspects that may be just as important and actually more interesting. If this can be expanded, the study would be outstanding.</p><p>Comments on revisions: This reviewer feels that the authors have addressed all issues.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97621.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors report describes a novel vaccine platform derived from a newly discovered organelle called a migrasome. First, the authors address a technical hurdle for using migrasomes as a vaccine platform. Natural migrasome formation occurs at low levels and is labor intensive, however, by understanding the molecular underpinning of migrasome formation, the authors have designed a method to make engineered migrasomes from cultures cells at higher yields utilizing a robust process. These engineered migrasomes behave like natural migrasomes. Next, the authors immunized mice with migrasomes that either expressed a model peptide or the SARS-CoV-2 spike protein. Antibodies against the spike protein were raised that could be boosted by a 2nd vaccination and these antibodies were functional as assessed by an in vitro pseudoviral assay. This new vaccine platform has the potential to overcome obstacles such as cold chain issues for vaccines like messenger RNA that require very stringent storage conditions.</p><p>Strengths:</p><p>The authors present very robust studies detailing the biology behind migrasome formation and this fundamental understanding was used to from engineered migrasomes, which makes it possible to utilize migrasomes as a vaccine platform. The characterization of engineered migrasomes is thorough and establishes comparability with naturally occurring migrasomes. The biophysical characterization of the migrasomes is well done, including thermal stability and characterization of the particle size (important characterizations for a good vaccine).</p><p>Weaknesses:</p><p>With a new vaccine platform technology, it would be nice to compare them head-to-head against a proven technology. The authors would improve the manuscript if they made some comparisons to other vaccine platforms such as a SARS-CoV-2 mRNA vaccine or even an adjuvanted recombinant spike protein. This would demonstrate a migrasome based vaccine could elicit responses comparable to a proven vaccine technology. Additionally, understanding the integrity of the antigens expressed in their migrasomes could be useful. This could be done by looking at functional monoclonal antibody binding to their migrasomes in a confocal microscopy experiment.</p><p>Updates after revision:</p><p>The revised manuscript has additional experiments that I believe improve the strength of evidence presented in the manuscript and address the weaknesses of the first draft. First, they provide a comparison to the antibody responses induced by their migrasome based platform to recombinant protein formulated in an adjuvant and show the response is comparable. Second, they provide evidence that the spike protein incorporated into their migrasomes retains structural integrity by preserving binding to monoclonal antibodies. Together, these results strengthen the paper significantly and support the claims that the novel migrasome based vaccine platform could be a useful in the vaccine development field.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97621.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Dongju</given-names></name><role specific-use="author">Author</role><aff><institution>Tsinghua University</institution><addr-line><named-content content-type="city">BEIJING</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Haifang</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University Third Hospital</institution><addr-line><named-content content-type="city">BEIJING</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wan</surname><given-names>Wei</given-names></name><role specific-use="author">Author</role><aff><institution>Tsinghua University</institution><addr-line><named-content content-type="city">BEIJING</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Zihui</given-names></name><role specific-use="author">Author</role><aff><institution>Tsinghua University</institution><addr-line><named-content content-type="city">BEIJING</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Sho</surname><given-names>Takami</given-names></name><role specific-use="author">Author</role><aff><institution>Tsinghua University</institution><addr-line><named-content content-type="city">BEIJING</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Yi</given-names></name><role specific-use="author">Author</role><aff><institution>Tsinghua University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xing</given-names></name><role specific-use="author">Author</role><aff><institution>Tsinghua University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Dou</surname><given-names>Longyu</given-names></name><role specific-use="author">Author</role><aff><institution>Migrasome Therapeutics</institution><addr-line><named-content content-type="city">BEIJING</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Qiang</given-names></name><role specific-use="author">Author</role><aff><institution>Princeton University</institution><addr-line><named-content content-type="city">Princeton</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Li</given-names></name><role specific-use="author">Author</role><aff><institution>Tsinghua University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Zhihua</given-names></name><role specific-use="author">Author</role><aff><institution>Tsinghua University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>This is an excellent study by a superb investigator who discovered and is championing the field of migrasomes. This study contains a hidden &quot;gem&quot; - the induction of migrasomes by hypotonicity and how that happens. In summary, an outstanding fundamental phenomenon (migrasomes) en route to becoming transitionally highly significant.</p><p>Strengths:</p><p>Innovative approach at several levels. Migrasomes - discovered by Dr Yu's group - are an outstanding biological phenomenon of fundamental interest and now of potentially practical value.</p><p>Weaknesses:</p><p>I feel that the overemphasis on practical aspects (vaccine), however important, eclipses some of the fundamental aspects that may be just as important and actually more interesting. If this can be expanded, the study would be outstanding.</p></disp-quote><p>We sincerely thank the reviewer for the encouraging and insightful comments. We fully agree that the fundamental aspects of migrasome biology are of great importance and deserve deeper exploration.</p><p>In line with the reviewer’s suggestion, we have expanded our discussion on the basic biology of engineered migrasomes (eMigs). A recent study by the Okochi group at the Tokyo Institute of Technology demonstrated that hypoosmotic stress induces the formation of migrasome-like vesicles, involving cytoplasmic influx and requiring cholesterol for their formation (DOI: 10.1002/1873-3468.14816, February 2024). Building on this, our study provides a detailed characterization of hypoosmotic stressinduced eMig formation, and further compares the biophysical properties of natural migrasomes and eMigs. Notably, the inherent stability of eMigs makes them particularly promising as a vaccine platform.</p><p>Finally, we would like to note that our laboratory continues to investigate multiple aspects of migrasome biology. In collaboration with our colleagues, we recently completed a study elucidating the mechanical forces involved in migrasome formation (DOI: 10.1016/j.bpj.2024.12.029), which further complements the findings presented here.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>The authors' report describes a novel vaccine platform derived from a newly discovered organelle called a migrasome. First, the authors address a technical hurdle in using migrasomes as a vaccine platform. Natural migrasome formation occurs at low levels and is labor intensive, however, by understanding the molecular underpinning of migrasome formation, the authors have designed a method to make engineered migrasomes from cultured, cells at higher yields utilizing a robust process. These engineered migrasomes behave like natural migrasomes. Next, the authors immunized mice with migrasomes that either expressed a model peptide or the SARSCoV-2 spike protein. Antibodies against the spike protein were raised that could be boosted by a 2nd vaccination and these antibodies were functional as assessed by an in vitro pseudoviral assay. This new vaccine platform has the potential to overcome obstacles such as cold chain issues for vaccines like messenger RNA that require very stringent storage conditions.</p><p>Strengths:</p><p>The authors present very robust studies detailing the biology behind migrasome formation and this fundamental understanding was used to form engineered migrasomes, which makes it possible to utilize migrasomes as a vaccine platform. The characterization of engineered migrasomes is thorough and establishes comparability with naturally occurring migrasomes. The biophysical characterization of the migrasomes is well done including thermal stability and characterization of the particle size (important characterizations for a good vaccine).</p><p>Weaknesses:</p><p>With a new vaccine platform technology, it would be nice to compare them head-tohead against a proven technology. The authors would improve the manuscript if they made some comparisons to other vaccine platforms such as a SARS-CoV-2 mRNA vaccine or even an adjuvanted recombinant spike protein. This would demonstrate a migrasome-based vaccine could elicit responses comparable to a proven vaccine technology.</p></disp-quote><p>We thank the reviewer for the thoughtful evaluation and constructive suggestions, which have helped us strengthen the manuscript.</p><p>Comparison with proven vaccine technologies:</p><p>In response to the reviewer’s comment, we now include a direct comparison of the antibody responses elicited by eMig-Spike and a conventional recombinant S1 protein vaccine formulated with Alum. As shown in the revised manuscript (Author response image 1), the levels of S1-specific IgG induced by the eMig-based platform were comparable to those induced by the S1+Alum formulation. This comparison supports the potential of eMigs as a competitive alternative to established vaccine platforms.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>eMigrasome-based vaccination showed similar efficacy compared with adjuvanted recombinant spike protein The amount of S1-specific IgG in mouse serum was quantified by ELISA on day 14 after immunization.</title><p>Mice were either intraperitoneally (i.p.) immunized with recombinant Alum/S1 or intravenously (i.v.) immunized with eM-NC, eM-S or recombinant S1. The administered doses were 20 µg/mouse for eMigrasomes, 10 µg/mouse (i.v.) or 50 µg/mouse (i.p.) for recombinant S1 and 50 µl/mouse for Aluminium adjuvant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97621-sa3-fig1-v1.tif"/></fig><p>Assessment of antigen integrity on migrasomes:</p><p>To address the reviewer’s suggestion regarding antigen integrity, we performed immunoblotting using antibodies against both S1 and mCherry. Two distinct bands were observed: one at the expected molecular weight of the S-mCherry fusion protein, and a higher molecular weight band that may represent oligomerized or higher-order forms of the Spike protein (Figure 5B in the revised manuscript).</p><p>Furthermore, we performed confocal microscopy using a monoclonal antibody against Spike (anti-S). Co-localization analysis revealed strong overlap between the mCherry fluorescence and anti-Spike staining, confirming the proper presentation and surface localization of intact S-mCherry fusion protein on eMigrasomes (Figure 5C in the revised manuscript). These results confirm the structural integrity and antigenic fidelity of the Spike protein expressed on eMigrasomes.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>I feel that the overemphasis on practical aspects (vaccine), however important, eclipses some of the fundamental aspects that may be just as important and actually more interesting. If this can be expanded, the study would be outstanding.</p><p>I know that the reviewers always ask for more, and this is not the case here. Can the abstract and title be changed to emphasize the science behind migrasome formation, and possibly add a few more fundamental aspects on how hypotonic shock induces migrasomes?</p><p>Alternatively, if the authors desire to maintain the emphasis on vaccines, can immunological mechanisms be somewhat expanded in order to - at least to some extent - explain why migrasomes are a better vaccine vehicle?</p><p>One way or another, this reviewer is highly supportive of this study and it is really up to the authors and the editor to decide whether my comments are of use or not.</p><p>My recommendation is to go ahead with publishing after some adjustments as per above.</p></disp-quote><p>We’d like to thank the reviewer for the suggestion. We have changed the title of the manuscript and modified the abstract, emphasizing the fundamental science behind the development of eMigrasome. To gain some immunological information on eMig illucidated antibody responses, we characterized the type of IgG induced by eM-OVA in mice, and compared it to that induced by Alum/OVA. The IgG response to Alum/OVA was dominated by IgG1. Quite differently, eM-OVA induced an even distribution of IgG subtypes, including IgG1, IgG2b, IgG2c, and IgG3 (Figure 4I in the revised manuscript). The ratio between IgG1 and IgG2a/c indicates a Th1 or Th2 type humoral immune response. Thus, eM-OVA immunization induces a balance of Th1/Th2 immune responses.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>The study is a very nice exploration of a new vaccine platform. This reviewer believes that a more head-to-head comparison to the current vaccine SARS-CoV-2 vaccine platform would improve the manuscript. This comparison is done with OVA antigen, but this model antigen is not as exciting as a functional head-to-head with a SARS-CoV-2 vaccine.</p></disp-quote><p>I think that two other discussion points should be included in the manuscript. First, was the host-cell protein evaluated? If not, I would include that point on how issues of host cell contamination of the migrasome could play a role in the responses and safety of a vaccine. Second, I would discuss antigen incorporation and localization into the platform. For example, the full-length spike being expressed has a native signal peptide and transmembrane domain. The authors point out that a transmembrane domain can be added to display an antigen that does not have one natively expressed, however, without a signal peptide this would not be secreted and localized properly. I would suggest adding a discussion of how a non-native signal peptide would be necessary in addition to a transmembrane domain.</p><p>We thank the reviewer for these thoughtful suggestions and fully agree that the points raised are important for the translational development of eMig-based vaccines.</p><p>(1) Host cell proteins and potential immunogenicity:</p><p>We appreciate the reviewer’s suggestion to consider host cell protein contamination. Considering potential clinical application of eMigrasomes in the future, we will use human cells with low immunogenicity such as HEK-293 or embryonic stem cells (ESCs) to generate eMigrasomes. Also, we will follow a QC that meets the standard of validated EV-based vaccination techniques.</p><p>(2) Antigen incorporation and localization—signal peptide and transmembrane domain:</p><p>We also agree with the reviewer’s point that proper surface display of antigens on eMigs requires both a transmembrane domain and a signal peptide for correct trafficking and membrane anchoring. For instance, in the case of full-length Spike protein, the native signal peptide and transmembrane domain ensure proper localization to the plasma membrane and subsequent incorporation into eMigs. In case of OVA, a secretary protein that contains a native signal peptide yet lacks a transmembrane domain, an engineered transmembrane domain is required. For antigens that do not naturally contain these features, both a non-native signal peptide and an artificial transmembrane domain are necessary. We have clarified this point in the revised discussion and explicitly noted the requirement for a signal peptide when engineering antigens for surface display on migrasomes.</p></body></sub-article></article>